Status:

COMPLETED

Glycemic Response to an Innovative Cookie to Promote Human Health

Lead Sponsor:

KU Leuven

Conditions:

Postprandial Glycemic Responses

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

The aim of this study is to investigate whether using a coarse wheat fraction in wire-cut cookie making induces a lower glycemic response in healthy subjects compared to wheat flour.

Detailed Description

This study has a double-blind, randomized, cross-over design. During each of the two study visits, healthy participants will consume a standard portion of cookies. One cookie formulation will present ...

Eligibility Criteria

Inclusion

  • Body mass index (BMI) range 18.5 - 25.0 kg/m2 at screening visit
  • Fasting whole blood glucose values \< 6.3 mmol/L
  • Regular diet with 3 meals a day (at least 5 times a week)
  • Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigators on the basis of medical history
  • Willingness to maintain habitual diet, physical activity pattern, and body weight throughout the trial
  • Willingness to abstain from alcohol consumption and to avoid vigorous physical activity for 24 h prior to study visits
  • Adequate level of understanding spoken and written English
  • Willingness to report lifestyle factors such as level of physical activity and perceived psychological stress
  • Willingness to provide informed consent to participate in the study

Exclusion

  • Failure to meet any one of the inclusion criteria
  • Recent participation in any clinical trial (\< 90 days)
  • Pregnant or lactating or wishing to become pregnant in the period of the study
  • Known history of AIDS, hepatitis, diabetes mellitus (Type I and II), cardiovascular disease, any pathology (or recent surgical event) of the gastrointestinal system or any current metabolic or endocrine disease
  • Alcohol consumption of \> 14 standard drinks for women and \> 21 standard drinks for men per week
  • Currently smoking (have smoked in the last 28 days) or willingness to smoke during the study period
  • Celiac disease or gluten intolerance
  • Use of medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids the last 4 weeks before the screening visit
  • Use of antibiotics during the last three months
  • Reported slimming or medically prescribed diet
  • Unwillingness or inability to comply with the experimental procedures and to follow the safety guidelines

Key Trial Info

Start Date :

September 5 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 24 2023

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT06005415

Start Date

September 5 2023

End Date

November 24 2023

Last Update

November 29 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

KU Leuven/UZ Leuven

Leuven, Vlaams-Brabant, Belgium, 3000